MKNK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Accordingly, the MNK1 inhibitor CGP 57380 was effective in preventing nuclear translocation of β-catenin in models of chronic myeloid leukemia and nasopharyngeal carcinoma in vitro and in vivo [34, 62].